Table 3

Diagonal linear discriminant analysis of NSCLC cell lines



Predicted sensitivity to EGFR TKI




Cell Line
 Experimental Sensitivity to EGFR TKI (erlotinib)
 Prediction based on analysis of mutational status alone (Exons 18–21)
 Genomic signature/DLDA









10-genes
 50-genes
 180-genes
Training
 A549
 No
 √
 √*
 √
 √

UKY-29
 No
 √
√
 √

H1650
 Yes
 √
 √
 √
 √

PC-9
 Yes
 √
 √
 √
 √

H3255
 Yes
 √
 √
 √
 √
Validation
 H358
 Yes
√
 √
 √

H460
 No
 √
 √
 √
 √

H1975
 No
 √



K562
 No
 √
 √
 √
 √

A431
 Yes
√
 √
 √




% Correct
 80%
 80%
 90%
 90%

Predictions of EGFR TKI sensitivity are denoted for ten cell lines used in training/validation. Column 2 demonstrates experimental sensitivity to an EGFR TKI, erlotinib (Table 1). Column 3 demonstrates prediction of sensitivity using mutational status of EGFR. Columns 4–6 denote prediction of sensitivity of the cell lines using the 10, 50, and 180 gene signatures in DLDA. √: denotes correct prediction based on experimental sensitivity to EGFR TKI. *: Leave-a-group-out cross-validation incorrectly predicts 3 of 8 replicates of this cell line.

Balko et al. BMC Genomics 2006 7:289   doi:10.1186/1471-2164-7-289